Mar 8 Patent in Israel granted for DNA-FACE™ Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
Dec 31, 2020 Patent in US granted for DNA-FACE™ Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
Nov 1, 2020 Funds from The National Centre for Research and Development The National Centre for Research and Development grant TECHMATSTRATEG-III/0042/2019 (2020-2023) received by the Institute...
Aug 27, 2020 Patent for EU Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
Aug 20, 2020 New publication in MethodsX international journal Detailed laboratory protocols, concerning the patented BioVentures Institute genetic engineering and protein functional programming,...
Aug 5, 2020 Patent for China We have been informed by Chineese Patent Office that our patent application no 201580028495.1, concerning our break-through recombinant...
Jul 1, 2020 Patent in US granted for DNA-FACE™ Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
Jun 23, 2020 Scientific publication Scientific publication in the area of industrial enzymes. A novel proteinase Onygena, an improved alternative to the ‘workhorse’ of...
May 28, 2020 Patent for Israel We have been informed by Israeli Patent Office that our patent application no 248011, concerning our break-through recombinant DNA...
Apr 16, 2020 Patent for Japan Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
